Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Q-TWiST of lenvatinib + everolimus in advanced RCC

Chung-Han Lee • 29 May 2020
ASCO 2020
Genitourinary Cancer Kidney Cancer Everolimus Lenvatinib

Chung Han-Lee, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of patients enrolled in the HOPE-205 study (NCT01136733). Analysis suggests that the combination of lenvatinib plus everolimus in advanced renal cell carcinoma results in increased time without significant side effects when compared to everolimus monotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Chung-Han Lee

The challenges and potential of triple therapies in non-clear cell RCC
1:38
The challenges and potential of triple therapies in non-clear cell RCC
Chung-Han Lee • 3 Jun 2023
Promising results of cabozantinib plus nivolumab in non-clear cell RCC
1:20
Promising results of cabozantinib plus nivolumab in non-clear cell RCC
Chung-Han Lee • 3 Jun 2023
Promising TKI-ICI combinations for non-clear cell RCC
1:06
Promising TKI-ICI combinations for non-clear cell RCC
Chung-Han Lee • 3 Jun 2023
KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCC
1:28
KEYNOTE-B61: first-line lenvatinib + pembrolizumab in non-clear cell RCC
Chung-Han Lee • 3 Jun 2023

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals